Pulmatrix (NASDAQ:PULM) Releases Quarterly Earnings Results

Pulmatrix (NASDAQ:PULM) announced its quarterly earnings results on Friday. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, FiscalAI reports.

Pulmatrix Stock Down 1.6%

NASDAQ PULM opened at $1.25 on Friday. The company has a market capitalization of $4.57 million, a price-to-earnings ratio of -1.02 and a beta of 1.94. Pulmatrix has a twelve month low of $1.16 and a twelve month high of $9.37. The stock has a fifty day simple moving average of $1.56 and a 200 day simple moving average of $2.73.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulmatrix in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Institutional Trading of Pulmatrix

An institutional investor recently bought a new position in Pulmatrix stock. Dimensional Fund Advisors LP acquired a new stake in Pulmatrix, Inc. (NASDAQ:PULM) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned 0.30% of Pulmatrix as of its most recent SEC filing. 11.84% of the stock is owned by institutional investors and hedge funds.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).